Research progress on the application of Sorafenib in biliary tract cancer
Biliary tract cancer(BTC)is a kind of digestive system tumor with strong proliferation and invasion,high malignancy,and poor prognosis.Affected by factors such as special anatomical location and hidden onset,most patients can no longer be radically cured by surgery at the time of treatment,and the median survival time＜1 year,which seriously threatens the life of patients,and also brings a huge burden to the family and society.Sorafenib is an anti-tumor drug with molecular targeting,which can target multiple sites on tumor cells and vascular endothelial cells,inhibit the growth and proliferation process of tumor tissue,and induce cells apoptosis.It has significant efficacy in BTC treatment,which brings new possibilities for improving patient prognosis.However,the drug resistance produced by the body in the course of treatment limits the efficacy of Sorafenib to a certain extent,which is also a key and difficult problem to be solved in future clinical.
NETL
NSTL
万方数据
